Evelo again misses primary goal in atopic dermatitis and will shutter study, lay off more staff
Evelo Biosciences said it will end work on an atopic dermatitis drug, lay off more staff and instead focus on a different candidate that’s poised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
